Literature DB >> 17465253

Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.

Minoru Kobayashi1, Kazumi Suzuki, Masahiro Yashi, Masayuki Yuzawa, Norio Takayashiki, Tatsuo Morita.   

Abstract

BACKGROUND: Although renal cell carcinoma (RCC) is considered to be an immunogenic tumor, the role of immunogenicity in this tumor for predicting treatment response has been little investigated. PATIENTS AND METHODS: Resected RCC specimens from 25 patients who received cytokine treatment for metastases were investigated using immunohistochemistry for CD83+ or S100+ dendritic cells (DCs), CD8+ T-cells, HLA-DR+ tumor cells, CD68+ tumor associated macrophages, microvascular density and vascular endotherial growth factor.
RESULTS: Among the examined parameters, DCs status showed predictive value, that is, higher numbers of CD83+ or S100+ cells in tumors were associated with favorable treatment response. However, only higher CD83 status, which indicates mature and activated DCs, contributed to better survival (p = 0.0339).
CONCLUSION: Increased tumor infiltration of mature DCs would be a predictor of treatment response and outcome in metastatic RCC patients, who receive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465253

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.

Authors:  Lichen Teng; Yongsheng Chen; Dexin Ding; Hongshuang Dai; Guobin Liu; Changfu Li
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

2.  Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

Authors:  Ainhoa-M Figel; Dorothee Brech; Petra U Prinz; Ulrike K Lettenmeyer; Judith Eckl; Adriana Turqueti-Neves; Josef Mysliwietz; David Anz; Nicole Rieth; Niklas Muenchmeier; Alexander Buchner; Stefan Porubsky; Sabine I Siegert; Stephan Segerer; Peter J Nelson; Elfriede Noessner
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

Review 3.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Authors:  Bryden Considine; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2019-03-08       Impact factor: 5.075

Review 4.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

5.  Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma.

Authors:  Peter Middel; Sven Brauneck; Werner Meyer; Heinz-Joachim Radzun
Journal:  BMC Cancer       Date:  2010-10-22       Impact factor: 4.430

Review 6.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 7.  Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.

Authors:  L M A Aparicio; I P Fernandez; J Cassinello
Journal:  Clin Transl Oncol       Date:  2017-04-13       Impact factor: 3.405

Review 8.  From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

Authors:  Jonathan Anker; Justin Miller; Nicole Taylor; Natasha Kyprianou; Che-Kai Tsao
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

9.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

Review 10.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Erika Vacchelli; Ilio Vitale; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fučíková; Isabelle Cremer; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.